Advertisement

International Journal of Hematology

, Volume 78, Issue 3, pp 270–271 | Cite as

Intensified Conditioning Regimen Has Only Limited Value for Patients with Progressive Multiple Myeloma

  • Naoki Takezako
  • Akiyoshi Miwa
  • Akira Tanimura
  • Chiho Inokuchi
  • Tateki Shikai
  • Noboru Yamagata
  • Atsushi Togawa
Letter to the Editor
  • 25 Downloads

Keywords

Multiple Myeloma Autologous Stem Cell Transplantation Total Body Irradiation Allogeneic Stem Cell Transplantation Methyl CCNU 

References

  1. 1.
    Attal M, Harousseau J-L, Stoppa AM, et al. Prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.New Engl J Med. 1996;335:91–97.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lahuerta JJ, Martinez-Lopez J, Grande C, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.Br J Haematol. 2000;109:138–147.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Desikan KR, Tricot G, Dhodapkar M, et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.Bone Marrow Transplant. 2000;25:483–487.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Abraham R, Chen C,Tsang R, et al. Intensification of the stem cell transplant induction regimen results in increased treatment- related mortality without improved outcome in multiple myeloma.Bone Marrow Transplant. 1999;24:1291–1297.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma.Blood. 1999;93:55–65.PubMedGoogle Scholar
  6. 6.
    Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.Cancer. 1975;36:842–854.CrossRefPubMedGoogle Scholar
  7. 7.
    Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Hoffbrand AV, Brown MC, Hirsch J, eds.Recent Advances in Haematology. Edinburgh: Churchill Livingstone; 1977:243–261.Google Scholar
  8. 8.
    Ashraf Badros, Bart Barlogie, Christopher Morris, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.Blood. 2001:97:2574–2579.CrossRefGoogle Scholar
  9. 9.
    Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.Blood. 1997;90:4206–4211.PubMedGoogle Scholar
  10. 10.
    Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle.Blood. 1996;87:1196–1198.PubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Naoki Takezako
    • 1
  • Akiyoshi Miwa
    • 1
  • Akira Tanimura
    • 1
  • Chiho Inokuchi
    • 1
  • Tateki Shikai
    • 1
  • Noboru Yamagata
    • 1
  • Atsushi Togawa
    • 1
  1. 1.Department of HematologyInternational Medical Center of JapanTokyoJapan

Personalised recommendations